Stock VIMTALABS VIMTA LABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vimta Labs Limited NSE India S.E.

Equities

VIMTALABS

INE579C01029

Biotechnology & Medical Research

Market Closed - NSE India S.E.
Other stock markets
 07:43:49 2024-04-26 am EDT 		5-day change 1st Jan Change
542.4 INR -3.21% Intraday chart for Vimta Labs Limited +20.58% +34.39%
Mar. 02 Vimta Labs Limited Receives Grant in Aid for Upgrading of Food Testing Laboratory At Vimta Life Sciences Facility Plot No.5, Mn Science Technology Park, Genome Valley, Shameerpet, Hyderabad, Telangana CI
Feb. 01 Transcript : Vimta Labs Limited, Q3 2024 Earnings Call, Feb 01, 2024

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 3,879 4,419 1,310 3,558 6,966 6,954
Enterprise Value (EV) 1 4,258 4,651 1,587 3,797 7,052 6,712
P/E ratio 23.6 x 17.5 x 19.1 x 16.6 x 17.2 x 14.7 x
Yield 1.14% 1% - 1.24% 0.63% 0.64%
Capitalization / Revenue 2.14 x 2.08 x 0.72 x 1.69 x 2.5 x 2.18 x
EV / Revenue 2.35 x 2.18 x 0.88 x 1.8 x 2.53 x 2.1 x
EV / EBITDA 9.35 x 8 x 5.22 x 7.06 x 8.71 x 7.01 x
EV / FCF -48.3 x 28.7 x 17.7 x 239 x 41.5 x 27.5 x
FCF Yield -2.07% 3.48% 5.66% 0.42% 2.41% 3.64%
Price to Book 2.55 x 2.58 x 0.76 x 1.83 x 2.98 x 2.47 x
Nbr of stocks (in thousands) 22,108 22,108 22,108 22,108 22,108 22,129
Reference price 2 175.4 199.9 59.25 161.0 315.1 314.2
Announcement Date 8/1/18 7/3/19 8/14/20 6/8/21 5/30/22 6/1/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 1,811 2,130 1,811 2,110 2,787 3,190
EBITDA 1 455.4 581 303.8 537.4 809.7 957.6
EBIT 1 298.4 383.8 94.52 306.6 576.4 650.4
Operating Margin 16.47% 18.02% 5.22% 14.53% 20.68% 20.39%
Earnings before Tax (EBT) 1 255.6 351.4 82.7 285.4 556.8 650
Net income 1 164.3 253.1 68.45 214 413.3 481.7
Net margin 9.07% 11.88% 3.78% 10.14% 14.83% 15.1%
EPS 2 7.430 11.45 3.096 9.680 18.32 21.35
Free Cash Flow 1 -88.23 161.9 89.87 15.88 169.8 244.1
FCF margin -4.87% 7.6% 4.96% 0.75% 6.09% 7.65%
FCF Conversion (EBITDA) - 27.87% 29.58% 2.96% 20.98% 25.49%
FCF Conversion (Net income) - 63.97% 131.29% 7.42% 41.1% 50.67%
Dividend per Share 2 2.000 2.000 - 2.000 2.000 2.000
Announcement Date 8/1/18 7/3/19 8/14/20 6/8/21 5/30/22 6/1/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 380 232 278 238 85.4 -
Net Cash position 1 - - - - - 242
Leverage (Debt/EBITDA) 0.8336 x 0.3986 x 0.9133 x 0.4434 x 0.1055 x -
Free Cash Flow 1 -88.2 162 89.9 15.9 170 244
ROE (net income / shareholders' equity) 11.4% 15.6% 3.97% 11.7% 19.3% 18.7%
ROA (Net income/ Total Assets) 8.22% 10.2% 2.45% 7.37% 12.4% 12.1%
Assets 1 2,000 2,478 2,799 2,905 3,336 3,967
Book Value Per Share 2 68.80 77.60 78.20 87.90 106.0 127.0
Cash Flow per Share 2 0.9000 1.210 2.490 2.800 4.890 13.80
Capex 1 243 165 158 331 298 478
Capex / Sales 13.44% 7.76% 8.72% 15.68% 10.68% 14.99%
Announcement Date 8/1/18 7/3/19 8/14/20 6/8/21 5/30/22 6/1/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. VIMTALABS Stock
  4. VIMTALABS Stock
  5. Financials Vimta Labs Limited